Latest news

• GSK two-drug trial in untreated HIV raises Gilead rivalry

  The recent FDA approval of single-tablet triple Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in the US and Europe is central to Gilead’s push-back, with some analysts predicting it could

• Gilead’s Biktarvy gets European approval, setting up battle with GSK

  The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

• The year of the blockbuster

  Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

• Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

  However Gilead has its own direct competitor, Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's Descovy, a combo of emtricitabine and tenofovir alafenamide.

• CHMP backs first-line use for AZ’s Tagrisso in lung cancer

  There was also good news at the CHMP meeting for Gilead Sciences’HIV division, with the panel giving its blessing to three-drug, fixed-dose therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).